Cortexyme Appoints Marwan Sabbagh, MD, to its Board of Directors
March 15 2022 - 07:00AM
Business Wire
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage
biopharmaceutical company pioneering upstream therapeutic
approaches to improve the lives of patients diagnosed with
degenerative diseases, today announced the appointment of Marwan
Noel Sabbagh, MD, FAAN, a board-certified neurologist and leading
expert in Alzheimer’s and dementia care, to the company’s Board of
Directors.
“Dr. Sabbagh’s deep expertise in neurological diseases and
extensive clinical development experience makes him a valuable
addition to the Cortexyme Board of Directors,” said Chris Lowe,
Cortexyme’s interim chief executive officer. “Cortexyme will
benefit greatly from his broad clinical experience as we advance
our proprietary pipeline and evaluate potential new indications and
molecules.”
“Based upon more than thirty years of clinical experience, I
believe that gingipain inhibition potentially offers a clinically
significant therapy for a variety of degenerative conditions,” said
Dr. Sabbagh. “I look forward to sharing my clinical expertise with
the Cortexyme team to further support the advancement of their
pipeline for the treatment of degenerative diseases.”
Marwan Noel Sabbagh, MD, FAAN, board-certified neurologist and
geriatric neurologist, hopes to work himself out of a job.
Considered one of the leading experts in Alzheimer’s and dementia,
Dr. Sabbagh has dedicated his career to finding a cure for
Alzheimer’s and other age-related neurodegenerative diseases. He is
a leading investigator for many prominent national Alzheimer’s
prevention and treatment trials.
Dr. Sabbagh is on the editorial boards of the Journal of
Alzheimer's Disease and Alzheimer’s and Dementia TRCI. He also is
editor in chief of Neurology and Therapy. He has authored and
co-authored more than 400 medical and scientific articles on
Alzheimer’s research. Dr. Sabbagh is the author of The Alzheimer’s
Answer: Reduce Your Risk and Keep Your Brain Healthy, with foreword
by Justice Sandra Day O’Connor, and of The Alzheimer’s Prevention
Cookbook: 100 Recipes to Boost Brain Health. He edited Palliative
Care for Advanced Alzheimer’s and Dementia: Guidelines and
Standards for Evidence Based Care and Geriatric Neurology,
published in 2014, Fighting for my Life: living in the shadow of
Alzheimer’s disease, published in 2019, and his latest book titled
Strong Heart, Sharp Mind was recently released in January 2022. He
has been recognized with numerous awards and has been a Fellow of
the American Academy of Neurology since 2004.
Dr. Sabbagh earned his undergraduate degree from the University
of California, Berkeley and his medical degree from the University
of Arizona in Tucson. He received his residency training in
neurology at Baylor College of Medicine, Houston, Texas, and
completed his fellowship in geriatric neurology and dementia at the
University of California, San Diego School of Medicine, where he
served on the faculty as assistant professor. Before rejoining the
faculty of the Barrow Neurological Institute, he was the Camille
and Larry Ruvo Endowed Chair for Brain Health and Director of the
Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas.
Prior to that, he was the director of the Banner Sun Health
Research Institute in Phoenix.
About Cortexyme
Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage
biopharmaceutical company pioneering upstream therapeutic
approaches designed to improve the lives of patients diagnosed with
degenerative diseases, including Alzheimer’s disease,
periodontitis, and oral potentially malignant disorders, among
others. Cortexyme’s innovative approach targets a specific,
infectious pathogen called P. gingivalis found in the brain of
Alzheimer’s patients and other organs and tied to degeneration and
inflammation in humans and animal models. The company’s causation
evidence for Alzheimer’s disease and the mechanism of its novel
therapeutic has been independently replicated and confirmed by
multiple laboratories around the world, as well as published in
peer-reviewed scientific journals. To learn more about Cortexyme,
visit www.cortexyme.com or follow @Cortexyme on Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220315005499/en/
Stacy Roughan Cortexyme, Inc. Vice President, Corporate
Communications & Investor Relations ir@cortexyme.com
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Mar 2023 to Mar 2024